Back to Companies
Aprea Therapeutics, Inc.
APRENasdaqCIK: 0001781983
Aprea Therapeutics, Inc. (APRE) shows 12 recent insider filings from 10 insiders, with all of them on the buy side. With $5.1K in purchases and $0 in sales, the recent tape is heavily weighted toward buying (a net purchase of $5.1K). Gilad Oren (President/CEO, Director) is the most active by dollar volume, and the single largest transaction was $61.7K by Gilad Oren. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$196.5K
Purchases
$5.1K
Sales
$0
Unique Insiders
10
Recent Insider Trades
12 loaded
| Jun 17 | APRE Aprea Therapeutics, Inc. | Gruia Gabriela | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | BIZZARI JEAN-PIERRE | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | Pamukcu Rifat | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | Seizinger Bernd R. | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | Peters Richard | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | HENNEMAN JOHN B III | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | Grissinger Michael | Director | Grant | $9.2K |
| Jun 17 | APRE Aprea Therapeutics, Inc. | Duey Marc | Director | Grant | $9.2K |
| Apr 1 | APRE Aprea Therapeutics, Inc. | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Other | $21.2K |
| Mar 16 | APRE Aprea Therapeutics, Inc. | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Grant | $30.9K |
| Mar 16 | APRE Aprea Therapeutics, Inc. | Gilad Oren | President/CEO, Director | Grant | $61.7K |
| Feb 2 | APRE Aprea Therapeutics, Inc. | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $5.1K |
12 filings